跳至主要内容
临床试验/CTIS2023-508154-25-00
CTIS2023-508154-25-00进行中(未招募)1 期

Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activity to Adalimumab on first line with therapeutic drug concentration: A randomized, multicentre, controlled VEDIAN trial. - 23CH214

Centre Hospitalier Universitaire De Saint Etienne0 个研究点目标入组 220 人开始时间: 2023年10月24日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
220

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Major patient and having given consent to participate in the study, Patients with Crohn's disease who have responded primarly to Adalimumab princeps or similar bio with loss of response to Adalimumab (40 mg every two weeks) with therapeutically adequate levels of ADA (> 7.5 µg/mL)., Patient affiliated to or entitled under a social security scheme

排除标准

  • Pregnant woman, Patients receiving enteral nutrition, Patient under legal protection or unable to give consent, Hemorrhagic rectocolitis or indeterminate colitis, Patients treated with concomitant immunosuppressive agents, Patient treated with an optimized dose of adalimumab, Primary non-responder to Adalimumab, Patient previously treated with infliximab or ustekinumab before adalimumab, Severe relapse defined by CDAI > 330, Patient with anoperineal Crohn's disease, Crohn's disease patient with transient or permanent stoma, Patient unable to perform MRI or VCE or ileocoloscopy or ultrasound less than one month before inclusion, Patients on corticosteroid therapy, Previous or current use of vedolizumab or ustekinumab for Crohn's disease or participation in a biological study, Concomitant use of immunomodulators, History of cancer, History of human immunodeficiency virus (HIV), immunodeficiency syndrome, central nervous system (CNS) demyelinating disease (including myelitis), neurological symptoms suggestive of demyelinating disease, chronic recurrent infection, active tuberculosis (received or untreated), severe infections such as sepsis and opportunistic infections., Patient with ileoanal pouchitis or ileorectal anastomosis, Patient with short small bowel syndrome as determined by investigator, Patients receiving total parenteral nutrition (TPN).

研究者

相似试验

Comparison of Vedolizumab treatment to Adalimumab... | 临床试验